Pcn290 - Use of PCR as a Surrogate Primary Endpoint in Drug Pivotal Trials in Neoadjuvant Early Breast Cancer in Eu: A Perspective From Regulators and Payers
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.372
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV